Developmental Control of Polycomb Subunit Composition by GATA Factors Mediates a Switch to Non-Canonical Functions
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
SUMMARY Polycomb Repressive Complex 2 (PRC2) plays crucial roles in transcriptional regulation and stem cell development. However, the context-specific functions associated with alternative subunits remain largely unexplored. Here we show that the related enzymatic subunits EZH1 and EZH2 undergo an expression switch during blood cell development. An erythroid-specific enhancer mediates transcriptional activation of EZH1, and a switch from GATA2 to GATA1 controls the developmental EZH1/2 switch by differential association with EZH1 enhancers. We further examine the in vivo stoichiometry of the PRC2 complexes by quantitative proteomics and reveal the existence of an EZH1-SUZ12 sub-complex lacking EED. EZH1 together with SUZ12 form a non-canonical PRC2 complex, occupy active chromatin, and positively regulate gene expression. Loss of EZH2 expression leads to repositioning of EZH1 to EZH2 targets. Thus, the lineage- and developmental stage-specific regulation of PRC2 subunit composition leads to a switch from canonical silencing to non-canonical functions during blood stem cell specification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361 · cited 1×
“310 Molecular Cell 57, 304–316, January 22, 2015 a2015 Elsevier Inc scale, EED and EZH2 highly colocalize with H3K27me3, and inversely correlate with H3K4me3 and H3K27me1, histone marks associated with active transcription (Bernstein et al., 2006; Cui et al., 2009).”
Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., Parker, K., Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., et al. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400129-mcp200 · Cited by 4,401 · cited 2×
“For quantitative proteomics by iTRAQ, multiprotein complexes from K562 stable cell lines expressing FLAG-Bio-tagged PRC2 subunits were purified and digested to peptides, labeled with iTRAQ reagents (AB SCIEX), combined, and analyzed by LC-MS/MS (Ross et al., 2004).”
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Capturing Chromosome Conformation
Dekker, J., Rippe, K., Dekker, M., & Kleckner, N. (2002) · Science · doi:10.1126/science.1067799 · Cited by 3,652 · cited 1×
“By chromosome conformation capture (3C) analysis (Dekker et al., 2002), we observed that the frequency of interaction between EZH1 promoter and the putative +46 enhancer is significantly higher than other tested regions (Figure 2A, bottom).”
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · cited 3×
“Mo recruitment of additional regulatory machinery (Di Croce and Helin, 2013; Margueron and Reinberg, 2011; Shen et al., 2009).”
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717 · cited 2×
“Implications for Therapeutic Targeting of PRC2 Functions in Hematopoietic Malignancies Owing to recent findings that aberrant expression or gain-offunctionmutations of EZH2, aswell as other PRC2 core subunits, are common in various malignancies including lymphoma, breast, and prostate cancers, intensive efforts have b…”
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · cited 1×
“, 2012 ; McCabe et al .”
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596 · cited 1×
“Whereas the role of EZH2 in H3K27me3-mediated transcriptional repression has been well established (Cao et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002; Müller et al., 2002), the function of EZH1-PRC2 remains elusive and controversial.”
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139 · cited 2×
“Importantly, evidence for inactivatingEZH2mutations inmyeloiddisease suggests a tumor-suppressor function for EZH2 in other cellular contexts (Ernst et al., 2010; Makishima et al., 2010).”
Shen, X., Liu, Y., Hsu, Y.-J., Fujiwara, Y., Kim, J., Mao, X., Yuan, G.-C., & Orkin, S. H. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.10.016 · Cited by 1,021
Self-citation
Cited by
Activity-by-contact model of enhancer–promoter regulation from thousands of CRISPR perturbations
Fulco, C. P., Nasser, J., Jones, T. R., Munson, G., Bergman, D. T., Subramanian, V., Grossman, S. R., Anyoha, R., Doughty, B. R., Patwardhan, T. A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0538-0 · Cited by 1,111
Targeting Polycomb systems to regulate gene expression: modifications to a complex story
Blackledge, N. P., Rose, N. R., & Klose, R. J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4067 · Cited by 361
Regulation of gene transcription by Polycomb proteins
Aranda, S., Mas, G., & Di Croce, L. (2015) · Science Advances · doi:10.1126/sciadv.1500737 · Cited by 336
Chemistries of bifunctional PROTAC degraders
Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313
GATA transcription factors in development and disease
Tremblay, M., Sanchez-Ferras, O., & Bouchard, M. (2018) · Development · doi:10.1242/dev.164384 · Cited by 254
EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex
Hsu, J. H.-R., Rasmusson, T., Robinson, J., Pachl, F., Read, J., Kawatkar, S., O’ Donovan, D. H., Bagal, S., Code, E., Rawlins, P., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.11.004 · Cited by 202
Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation
Gu, Z., Liu, Y., Cai, F., Patrick, M., Zmajkovic, J., Cao, H., Zhang, Y., Tasdogan, A., Chen, M., Qi, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0152 · Cited by 173
“G12D/EED-KO phenocopied G12D/E1E2-DKO, consistent with the requirement for EED in both EZH1- and EZH2-containing PRC2 (23, 38).”
BackgroundSelf-citationEmerging roles for Polycomb proteins in cancer
Pasini, D., & Di Croce, L. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.03.013 · Cited by 133
Polycomb repressive complexes in hematological malignancies
Iwama, A. (2017) · Blood · doi:10.1182/blood-2017-02-739490 · Cited by 55
Shaikho, E. M., Farrell, J. J., Chui, D. H. K., Sebastiani, P., & Steinberg, M. H. (2018) · doi:10.1101/304899 · Cited by 5
Metadata
- Authors
- Xu, J., Shao, Z., Li, D., Xie, H., Kim, W., Huang, J., Taylor, J. E., Pinello, L., Glass, K., Jaffe, J. D., Yuan, G.-C., & Orkin, S. H.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 57
- Issue
- 2
- Pages
- 304-316
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W2054158156
- Cited by
- 150
- References
- 16
- FWCI
- 8.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.